Asian Penny Stocks To Watch In October 2026

As the global market grapples with inflation pressures and shifts in investment sentiment, Asian markets have shown resilience amidst these challenges. For those interested in exploring opportunities within smaller or newer companies, penny stocks—though an older term—remain a relevant area of interest. These stocks can offer a unique blend of value and growth potential when backed by strong financials, making them intriguing options for investors seeking to uncover hidden gems in the market.

Let's review some notable picks from our screened stocks.

Shanghai Yanhua Smartech Group (SZSE:002178)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shanghai Yanhua Smartech Group Co., Ltd. operates in energy conversion, the medical field, and smart city brand businesses in China with a market cap of CN¥3.50 billion.

Operations: The company generates CN¥369.34 million from its Green Smart City Service segment.

Market Cap: CN¥3.5B

Shanghai Yanhua Smartech Group Co., Ltd. operates with a market cap of CN¥3.50 billion, generating CN¥369.34 million from its Green Smart City Service segment. Despite recent financial challenges, including a net loss of CN¥11.37 million for H1 2026 and declining revenue compared to the previous year, the company maintains strong liquidity with short-term assets exceeding liabilities and more cash than debt. The management team is experienced, though the board is relatively new with an average tenure of 2.3 years. The company also has a sufficient cash runway for over three years under current conditions.

• Unlock comprehensive insights into our analysis of Shanghai Yanhua Smartech Group stock in this financial health report.
• Explore historical data to track Shanghai Yanhua Smartech Group's performance over time in our past results report.

Xiamen Hexing Packaging Printing (SZSE:002228)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Xiamen Hexing Packaging Printing Co., Ltd. is an integrated packaging and printing company involved in the research, design, development, production, distribution, sale, and warehousing of various packaging products both in China and internationally, with a market cap of CN¥3.72 billion.

Operations: The company generates CN¥10.57 billion in revenue from its packaging manufacturing industry segment.

Market Cap: CN¥3.72B

Xiamen Hexing Packaging Printing Co., Ltd. demonstrates a mixed financial profile within the penny stock sector. While the company boasts a solid market cap of CN¥3.72 billion and generates substantial revenue from its packaging segment, recent earnings have declined, with net income dropping to CN¥94.91 million for H1 2026 compared to the previous year. The company's short-term assets comfortably cover both short and long-term liabilities, indicating financial stability despite challenges such as low profit margins and increased debt levels over time. Recent inclusion in the S&P Global BMI Index highlights its growing recognition in broader markets.

• Take a closer look at Xiamen Hexing Packaging Printing's potential here in our financial health report.
• Assess Xiamen Hexing Packaging Printing's future earnings estimates with our detailed growth reports.

Guizhou Bailing Group Pharmaceutical (SZSE:002424)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Guizhou Bailing Group Pharmaceutical Co., Ltd. researches, develops, produces, and sells medicines in China with a market cap of CN¥6.29 billion.

Operations: The company generates revenue of CN¥2.56 billion from its operations in China.

Market Cap: CN¥6.29B

Guizhou Bailing Group Pharmaceutical faces challenges within the penny stock sector, with its recent earnings report showing a decline in revenue to CN¥970.49 million for H1 2026 from CN¥1.46 billion the previous year. Despite being unprofitable and having increased losses over five years, the company maintains satisfactory debt levels with a net debt to equity ratio of 27%. While short-term assets exceed long-term liabilities, they fall short of covering short-term liabilities. The management team is experienced, averaging an 11.5-year tenure, providing stability amid financial volatility and operational adjustments reflected in recent bylaw amendments.

• Get an in-depth perspective on Guizhou Bailing Group Pharmaceutical's performance by reading our balance sheet health report here.
• Understand Guizhou Bailing Group Pharmaceutical's track record by examining our performance history report.

Taking Advantage

• Unlock more gems! Our Asian Penny Stocks screener has unearthed 1,079 more companies for you to explore.Click here to unveil our expertly curated list of 1,082 Asian Penny Stocks.
• Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com